Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-03
2007-07-03
McKenzie, Thomas (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S320000, C514S327000, C546S192000, C546S196000, C546S201000, C546S225000, C546S226000, C546S227000
Reexamination Certificate
active
09732241
ABSTRACT:
This invention relates to hindered carbamate derivatives that are muscarinic receptor antagonists, pharmaceutical compositions comprising such compounds, and methods of preparing these compounds.
REFERENCES:
patent: 4567178 (1986-01-01), Eberlein et al.
patent: 4587046 (1986-05-01), Goodman et al.
patent: 4675326 (1987-06-01), Amitai et al.
patent: 5621010 (1997-04-01), Sueda et al.
patent: 5691323 (1997-11-01), Thompson et al.
patent: 0419397 (1991-03-01), None
patent: 0747355 (1996-12-01), None
patent: 0863141 (1998-09-01), None
patent: 0930298 (1999-07-01), None
patent: 93/20071 (1993-10-01), None
patent: 95/06635 (1995-03-01), None
patent: 98/03632 (1998-01-01), None
patent: 99/31086 (1999-06-01), None
Takeuchi, Makoto,.et al. , “Preparation of heterocyclyl carbomate derivatives with muscarine M3 receptor antagonism”,Retrieved from STN Database Accession No. 123:285789, (Mar. 9, 1995).
Barlow, R.B., et al., “A further search for selective antagonists at M2-muscarinic receptors”,Br. J. Pharmac., 89, pp. 837-843, (1986).
Bonner, T.I., et al., “Identification of a Family of Muscarinic Acetylcholine Receptor Genes”,Science, 237, pp. 527-532, (Jul. 31, 1987).
Carrithers, M.D., et al., “Synthesis and characterization of bivalent peptide ligands targeted to G-protein-coupled receptors”,Chemistry&Biology, 3 (7), pp. 537-542, (1996).
Eglen, R.M., et al., “Muscarinic Receptor Subtypes: Pharmacology and Therapeutic Potential”,DN&P, 10 (8), pp. 462-469, (Oct. 1997).
Fisher, A., “Muscarinic agonists for the treatment of Alzheimer's disease: progress and perspectives”,Exp. Opin. Invest. Drugs, 6 (10), Investigational Drugs—Review: Central & Peripheral Nervous Systems, pp. 1395-1411, (1997).
Goyal, R.K., “Muscarinic Receptor Subtypes: Physiology and Clinical Implications”,The New England Journal of Medicine, 321 (15), pp. 1022-1029, (Oct. 12, 1989).
Graul, A., et al., “Darifenacin—Agent for Irritable Bowel Syndrome Agent for Urinary Incontinence Muscarinic M3 Antagonist”,Drugs of the Future, 21 (11), pp. 1105-1108, (1996).
Graul, A., et al., “Tolterodine—Agent for Urinary Incontinence Muscarinic Receptor Antagonist”,Drugs of the Future, 22 (7), pp. 733-737, (1997).
Hulme, E.C., et al., “Muscarinic Receptor Subtypes”,Annu. Rev. Pharmacol. Toxicol., 30, pp. 633-673, (1990).
Ishihara, Y., et al., “Central Cholinergic Agents. III. Synthesis of 2-Alkoxy-2,8-diazaspiro[4,5]decane-1,3-diones as Muscarinic Agonists”,Chem. Pharm. Bull., 40 (5), pp. 1177-1185, (1992).
Jakubik, J., et al., “Positive Cooperativity of Acetylcholine and Other Agonists with Allosteric Ligands on Muscarinic Acetylcholine Receptors”,Molecular Pharmacology, 52, pp. 172-179, (1997).
Kostenis, E., et al., “Evidence for a multiple binding mode of bispyridinium-type allosteric modulators of muscarinic receptors”,European Journal of Pharmacology, 314, pp. 385-392, (1996).
Kostenis, E., et al., “Side Chain Variations in Bispyridinium-Type Allosteric Modulators of M2-Cholinoceptors”,Life Science, 56 (11/12), Abstract No. 13, p. 1009, (1995).
LeBoulluec, K.L., et al., “Bivalent Indoles Exhibiting Serotonergic Binding Affinity”,Bioorganic&Medicinal Chemistry Letters, 5 (2), pp. 123-126, (1995).
Martel, A.M., et al., “Revatropate—Bronchodilator Muscarinic M3 Antagonist”,Drugs of the Future, 22 (2), pp. 135-137, (1997).
Melchiorre, C., et al., “Antimuscarinic action of methoctramine, a new cardioselective M-2 muscarinic receptor antagonist, alone and in combination with atropine and gallamine”,European Journal of Pharmacology, 144, pp. 117-124, (1987).
Melchiorre, C., et al., “Polymethylene tetraamines ad muscarinic receptor probes”,TiPS, Supplement, pp. 55-59, (Dec. 1989).
Melchiorre, C., et al., “The Design of Novel Methoctramine-Related Tetraamines as Muscarinic Receptor Subtype Selective Antagonists”,Life Sciences, 56 (11/12), pp. 837-844, (1995).
Moser, U., et al., “Aliphatic and Hererocyclic Analogues of Arecaidine Propargyl Ester”,Arzneim-Forsch./Drug Res., 45 (I) Nbr. 4, pp. 449-455, (1995).
Piergentili, A., et al., “Synthesis and Muscarinic Receptors Affinity of a Series of Antagonist Bivalent Ligands”,IL Farmaco, 49 (2), pp. 83-87, (1994).
Portoghese, P.S., “The Role of Concepts in Structure—Activity Relationships Studies of Opioid Ligands”,Journal of Medicinal Chemistry, 35 (11), pp. 1927-1937, (1992).
Shuker, S.B., et al., “Discovering High-Affinity Ligands for Proteins: SAR by NMR”,Science, 274, pp. 1531-1533, (Nov. 29, 1996).
Sowell, Sr., J.W., et al., “Synthesis and Cholinergic Properties of Bis [[(dimethylamino)methyl]furanyl] Analogues of Ranitidine”,J. Med. Chem., 35, pp. 1102-1108, (1992).
Watson, N., et al., “Actions of methoctramine, a muscarinic M2 receptor antagonist, on muscarinic and nicotinic cholinoceptors in guinea-pig airways in vivo and in vitro”,Br. J. Pharmacology, 105, pp. 107-112, (1992).
Mammen Mathai
Oare David
Covington Raymond
Eberle Shelley
Hagenah Jeffrey A.
McKenzie Thomas
Theravance Inc.
LandOfFree
Therapeutic carbamates does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic carbamates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic carbamates will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3803856